Expert Opinion on Drug Delivery
基本情報
Expert Opinion on Drug Delivery (1742-5247; 1744-7593) is a MEDLINE-indexed, international subscription-based journal publishing rigorously peer-reviewed review articles in drug delivery. Articles cover all aspects of drug delivery research, from initial concept to potential therapeutic application and final relevance in clinical use. Each article is structured to incorporate the author’s own expert opinion on the scope for future development. The journal welcomes: Reviews covering delivery technologies, vehicles and devices; nanotechnology; novel formulations; the delivery of specific drug and therapeutic classes; gene/vaccine delivery strategies; modes of entry into the body and applications in certain diseases and disorders Technology evaluations reviewing a particular drug delivery technology Original research contributions are welcomed in the form of: - Delivery technologies, vehicles, formulations and devices; - The delivery of specific drugs and therapeutic classes; - Modes of entry into the body and applications in certain diseases and disorders. Editorials commenting on the various drug delivery strategies which have been, and are being, explored Guidelines on the application of specific drug delivery systems, or in specific disease indications. The audience for the journal consists of scientists and managers in the healthcare and pharmaceutical industry, academic pharmaceutical scientists and others closely involved in the delivery of drugs and other therapeutic agents. Comprehensive coverage in each review is complemented by the unique Expert Collection format and includes the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results; Article Highlights – an executive summary of the author’s most critical points. Once your paper has been assessed for suitability by the Editorial Team, it will then be double-anonymous peer-reviewed by independent, expert referees. Publish in 3 weeks from submission with Accelerated Publication. Reach an international clinical and medical audience alongside other key option leaders in your field by publishing with Expert Opinion on Drug Delivery, part of the Expert Collection brand.
CiteScore
| 分野 | ランク | パーセンタイル |
|---|---|---|
Pharmacology, Toxicology and PharmaceuticsPharmaceutical Science |
13 / 183 | 93% |
ジャーナル統計
投稿情報
投稿サイト:
https://mc.manuscriptcentral.com/eodd関連論文
Correction: High throughput first-principles calculations of bixbyite oxides for TCO applications
Nasrin Sarmadian, Rolando Saniz, Bart Partoens, Dirk Lamoen, Kalpana Volety, Guido Huyberechts, Johan Paul
DOI: 10.1039/C4CP90183E
Thermodynamic and kinetic characterization of transmembrane helix association
Aiswarya B. Pawar, Sneha A. Deshpande, Srinivasa M. Gopal, Tsjerk A. Wassenaar, Chaitanya A. Athale, Durba Sengupta
DOI: 10.1039/C4CP03732D
A novel two-dimensional MgB6 crystal: metal-layer stabilized boron kagome lattice
Sheng-Yi Xie, Xian-Bin Li, Nian-Ke Chen, Yeliang Wang, Shengbai Zhang, Hong-Bo Sun
DOI: 10.1039/C4CP03728F
An experimental and theoretical study of the gas phase kinetics of atomic chlorine reactions with CH3NH2, (CH3)2NH, and (CH3)3N
J. M. Nicovich, S. Mazumder, P. L. Laine, Y. Tang, A. J. C. Bunkan, C. J. Nielsen
DOI: 10.1039/C4CP03801K
Non-universal tracer diffusion in crowded media of non-inert obstacles
Surya K. Ghosh, Andrey G. Cherstvy
DOI: 10.1039/C4CP03599B
Ligand(s)-to-metal charge transfer as a factor controlling the equilibrium constants of late first-row transition metal complexes: revealing the Irving–Williams thermodynamical series
Pradeep R. Varadwaj, Arpita Varadwaj, Bih-Yaw Jin
DOI: 10.1039/C4CP03953J
Concentration effects on intrachain polaron recombination in conjugated polymers
Luiz Antonio Ribeiro Junior, Wiliam Ferreira da Cunha, Antonio Luciano de Almeida Fonseca, Ricardo Gargano, Geraldo Magela e Silva
DOI: 10.1039/C4CP04514A
Reverse hydrotropy by complex formation
Kamil Wojciechowski, Thomas Gutberlet, Vikram Singh Raghuwanshi, Ann Terry
DOI: 10.1039/C4CP03835E
Tailoring the interface of an immiscible polymer blend by a mutually miscible homopolymer grafted onto graphene oxide: outstanding mechanical properties
Goutam Prasanna Kar, Sourav Biswas, Suryasarathi Bose
DOI: 10.1039/C4CP04481A
こちらもおすすめ
1-{3-[5-(エチルカルボンイル)-2,4-ジメチル-1H-ピロロール-3-基]プロパニル}ピペリジン-4-カルボン酸について、適用される法規ガイドラインは何ですか?
この化合物はCAS番号1142209-81-1であり、GHS分類では corrosive (腐食性物質) と classified (分類物質) として指定され...
2,2-二氟-1,3-ベンゾジオキサン-5-カルボキシlic酸とは何ですか?
2,2-二氟-1,3-ベンゾジオキサン-5-カルボキシlic酸は、CAS番号656-46-2の化合物で、化学式はC8H4F2O4です。この化合物は白色の結晶性粉...
8-氯-4-色原酮の代替品はありますか?
8-氯-4-色原酮(CAS番号: 49701-11-3)の代替品には、他の色原酮類似物や、構造が似ている化合物があります。例えば、8-メチル-4-色原酮や、他の...
エチル6,6-ジメチル-4,5,6,7-テトラヒドロ-1H-インドアゼー-3-カルボキシレートとは何ですか?
エチル6,6-ジメチル-4,5,6,7-テトラヒドロ-1H-インドアゼー-3-カルボキシレートは、CAS番号1233243-56-5を有する化合物です。これは有...
4-叔丁基-6-氯-嘧啶に適用される法規ガイドラインは何ですか?
4-叔丁基-6-氯-嘧啶はCAS番号3435-24-3で、GHS分類では毒性物質とみなし、GHSの危険性分類が適用されます。REACH規則では登録が必要で、Eu...
維库溴铵杂质Bはどのように合成されますか?
維库溴铵杂质Bは、アンドロステンデンから始まり、一連の合成反応、包括的な選択性と高い収率で合成されます。具体的には、ブロミド化、酸化、ジマーゼ反応、アミド化など...
2-(4-氟苄基)-吡咯烷の物理化学的性質は何ですか?
CAS番号350017-04-8の2-(4-氟苄基)-吡咯烷は、結晶性の白色粉末です。分子量は199.17 g/molで、水に溶けにくいです。化学反応では比較的...
3-喹啉甲醛(2-チロール-8-エチル)は安全ですか?
3-喹啉甲醛(2-チロール-8-エチル)は一定の毒性を持つため、取扱には注意が必要です。使用する際は適切な防護具を着用し、密閉容器で保管・搬送し、直接的な接触を...
エチル3-(ヒドロキシメチル)-1H-ピロール-2-カルボキシレートはどのように保存すればよいですか?
エチル3-(ヒドロキシメチル)-1H-ピロール-2-カルボキシレートは、室温(25℃)以下で保存し、直射日光を避け、乾燥した環境で保管することが推奨されます。ま...

















![2-Bromodibenzo[b,d]furan structure 2-Bromodibenzo[b,d]furan structure](https://static.chemtradehub.com/structs/86-/86-76-0-1814.webp)